Additional studies on the roles, pathways, and interactions of TPD52, KLF9, miR-223, and PKC may give valuable insights into the progression of ovarian cancer and assist in identifying novel therapeutic targets. This evidence concerns the gene TPD52 and ovarian carcinoma.